Humana Inc.
Humana Inc. HUM Peers
See (HUM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HUM | $228.75 | -9.53% | 27.61B | 16.14 | $14.17 | +1.53% |
| UNH | $311.22 | -17.83% | 282.32B | 13.03 | $23.89 | +2.70% |
| ANTM | $482.58 | +2.71% | 114.59B | 18.99 | $25.41 | +1.75% |
| ELV | $375.26 | -9.94% | 84.78B | 14.60 | $25.71 | +1.75% |
| CI | $301.93 | -4.38% | 80.66B | 16.84 | $17.93 | +1.89% |
| CVS | $60.50 | -6.65% | 76.53B | 14.44 | $4.19 | +4.35% |
| CNC | $58.96 | -6.23% | 29.34B | 8.70 | $6.78 | N/A |
| MOH | $310.38 | -5.28% | 16.82B | 14.99 | $20.70 | N/A |
| OSCR | $16.91 | +0.51% | 3.70B | 169.05 | $0.10 | N/A |
| ALHC | $14.05 | -5.83% | 2.78B | -29.89 | -$0.47 | N/A |
Stock Comparison
HUM vs UNH Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, UNH has a market cap of 282.32B. Regarding current trading prices, HUM is priced at $228.75, while UNH trades at $311.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas UNH's P/E ratio is 13.03. In terms of profitability, HUM's ROE is +0.10%, compared to UNH's ROE of +0.32%. Regarding short-term risk, HUM is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ANTM Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, ANTM has a market cap of 114.59B. Regarding current trading prices, HUM is priced at $228.75, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas ANTM's P/E ratio is 18.99. In terms of profitability, HUM's ROE is +0.10%, compared to ANTM's ROE of +0.14%. Regarding short-term risk, HUM is more volatile compared to ANTM. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs ELV Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, ELV has a market cap of 84.78B. Regarding current trading prices, HUM is priced at $228.75, while ELV trades at $375.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas ELV's P/E ratio is 14.60. In terms of profitability, HUM's ROE is +0.10%, compared to ELV's ROE of +0.14%. Regarding short-term risk, HUM is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs CI Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, CI has a market cap of 80.66B. Regarding current trading prices, HUM is priced at $228.75, while CI trades at $301.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas CI's P/E ratio is 16.84. In terms of profitability, HUM's ROE is +0.10%, compared to CI's ROE of +0.12%. Regarding short-term risk, HUM is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs CVS Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, CVS has a market cap of 76.53B. Regarding current trading prices, HUM is priced at $228.75, while CVS trades at $60.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas CVS's P/E ratio is 14.44. In terms of profitability, HUM's ROE is +0.10%, compared to CVS's ROE of +0.07%. Regarding short-term risk, HUM is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs CNC Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, CNC has a market cap of 29.34B. Regarding current trading prices, HUM is priced at $228.75, while CNC trades at $58.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas CNC's P/E ratio is 8.70. In terms of profitability, HUM's ROE is +0.10%, compared to CNC's ROE of +0.13%. Regarding short-term risk, HUM is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs MOH Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, MOH has a market cap of 16.82B. Regarding current trading prices, HUM is priced at $228.75, while MOH trades at $310.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas MOH's P/E ratio is 14.99. In terms of profitability, HUM's ROE is +0.10%, compared to MOH's ROE of +0.26%. Regarding short-term risk, HUM is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs OSCR Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, OSCR has a market cap of 3.70B. Regarding current trading prices, HUM is priced at $228.75, while OSCR trades at $16.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas OSCR's P/E ratio is 169.05. In terms of profitability, HUM's ROE is +0.10%, compared to OSCR's ROE of +0.11%. Regarding short-term risk, HUM is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ALHC Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, ALHC has a market cap of 2.78B. Regarding current trading prices, HUM is priced at $228.75, while ALHC trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas ALHC's P/E ratio is -29.89. In terms of profitability, HUM's ROE is +0.10%, compared to ALHC's ROE of -0.81%. Regarding short-term risk, HUM is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs CLOV Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, CLOV has a market cap of 1.73B. Regarding current trading prices, HUM is priced at $228.75, while CLOV trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas CLOV's P/E ratio is -37.78. In terms of profitability, HUM's ROE is +0.10%, compared to CLOV's ROE of -0.07%. Regarding short-term risk, HUM is more volatile compared to CLOV. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs BHG Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, BHG has a market cap of 130.51M. Regarding current trading prices, HUM is priced at $228.75, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas BHG's P/E ratio is -0.12. In terms of profitability, HUM's ROE is +0.10%, compared to BHG's ROE of +3.25%. Regarding short-term risk, HUM is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs BMGL Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, BMGL has a market cap of 84.54M. Regarding current trading prices, HUM is priced at $228.75, while BMGL trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas BMGL's P/E ratio is 50.00. In terms of profitability, HUM's ROE is +0.10%, compared to BMGL's ROE of N/A. Regarding short-term risk, HUM is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs MRAI Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, MRAI has a market cap of 19.66M. Regarding current trading prices, HUM is priced at $228.75, while MRAI trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas MRAI's P/E ratio is -0.45. In terms of profitability, HUM's ROE is +0.10%, compared to MRAI's ROE of +0.93%. Regarding short-term risk, HUM is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs NIVF Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, NIVF has a market cap of 2.44M. Regarding current trading prices, HUM is priced at $228.75, while NIVF trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas NIVF's P/E ratio is -0.01. In terms of profitability, HUM's ROE is +0.10%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, HUM is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs IVF Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 27.61B. In comparison, IVF has a market cap of 2.11M. Regarding current trading prices, HUM is priced at $228.75, while IVF trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 16.14, whereas IVF's P/E ratio is -0.07. In terms of profitability, HUM's ROE is +0.10%, compared to IVF's ROE of N/A. Regarding short-term risk, HUM is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.